Christine Chung L.
Corporate Officer/Principal bei FIBROGEN, INC.
Vermögen: 209 460 $ am 30.04.2024
Profil
Christine Chung L. is currently the Chairman & Manager at Beijing Falikang Pharmaceutical Co. Ltd.
since 2020.
She is also the Managing Director at FibroGen (China) Medical Technology Development Co. Ltd.
since 2019, the Director at FibroGen International (Cayman) Ltd.
since 2019, the Director at FibroGen International (Hong Kong) Ltd.
since 2018, and the Senior Vice President-China Operations at FibroGen, Inc. since 2007.
Previously, she worked as the Vice President-Business Development at eMed Technologies Corp.
She completed her undergraduate degree at Harvard University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
FIBROGEN, INC.
0,21% | 31.03.2024 | 205 353 ( 0,21% ) | 209 460 $ | 30.04.2024 |
Aktive Positionen von Christine Chung L.
| Unternehmen | Position | Beginn |
|---|---|---|
| FIBROGEN, INC. | Corporate Officer/Principal | 01.01.2007 |
FibroGen (China) Medical Technology Development Co. Ltd.
 FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Vorstandsvorsitzender | 01.01.2019 |
Beijing Falikang Pharmaceutical Co. Ltd.
 Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Vorsitzender | 27.09.2020 |
| FibroGen International (Hong Kong) Ltd. | Direktor/Vorstandsmitglied | 01.01.2018 |
| FibroGen International (Cayman) Ltd. | Direktor/Vorstandsmitglied | 01.01.2019 |
Ehemalige bekannte Positionen von Christine Chung L.
| Unternehmen | Position | Ende |
|---|---|---|
eMed Technologies Corp.
 eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Corporate Officer/Principal | - |
Ausbildung von Christine Chung L.
| Harvard University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
eMed Technologies Corp.
eMed Technologies Corp. Packaged SoftwareTechnology Services eMed Technologies Corp. developed medical software technologies. It combined PACS, image management, web-based results distribution and web communications into a solution that empowered radiologists to manage more procedures, improve service and gain a competitive edge. It was headquartered in Burlington, MA. | Technology Services |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | Health Technology |
| FibroGen International (Cayman) Ltd. | |
| FibroGen International (Hong Kong) Ltd. | |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | Health Technology |